Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products

Value in Health(2020)10.1016/j.jval.2020.06.014Source: DataRank Database

Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products is a research paper published in Value in Health (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.64)OA: greenTopics (48)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Antonio J. Trujillo ORCID,G. Caleb Alexander ORCID,Jodi B Segal ORCID,Morgane C. Mouslim ORCID

Live enrichment

PubMed:33248515 OpenAlex:https://openalex.org/W3093982314

NHLBI NIH HHS

Grant: T32 HL139426

FWCI

0.64

Citation Percentile

0.7%

Influential Citations

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7748066

HYBRIDhttp://www.valueinhealthjournal.com/article/S1098301520343515/pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7748066

publisherhttps://api.elsevier.com/content/article/PII:S1098301520343515?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1098301520343515?httpAccept=text/plain

Fields of Study

Biosimilars and Bioanalytical MethodsNeutropenia and Cancer InfectionsMedication Adherence and ComplianceMedicineBiosimilar PharmaceuticalsCost SavingsDrug CostsFemaleFilgrastimHealth ExpendituresHumansInsurance Claim ReviewInsurance, HealthInterrupted Time Series AnalysisLongitudinal StudiesMaleMiddle AgedUnited States

MeSH Terms

FilgrastimHealth ExpendituresFemaleHumansInsurance Claim ReviewInsurance, HealthLongitudinal StudiesMaleMiddle AgedUnited StatesDrug CostsCost SavingsBiosimilar PharmaceuticalsInterrupted Time Series Analysis

Keywords

FilgrastimBiosimilarMedicinePaymentCost sharingMedical prescriptionBusinessInternal medicinePharmacologyGranulocyte colony-stimulating factorFinanceChemotherapybiosimilarscommercial insuranceinsurer paymentspatient out-of-pocket costs

Sustainable Development Goals

SDG 0: Partnerships for the goals